2-(1-methyl-4-phenyl-1H-imidazol-2-ylethynyl)-quinazoline | 1429781-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1-methyl-4-phenyl-1H-imidazol-2-ylethynyl)-quinazoline
• 英文别名: 2-[2-(1-methyl-4-phenylimidazol-2-yl)ethynyl]quinazoline；2-[2-(1-Methyl-4-phenyl-1H-imidazol-2-yl)ethynyl]quinazoline
• CAS: 1429781-02-1
• 化学式: C₂₀H₁₄N₄
• 分子量: 310.358
• InChiKey: PAERWMWABXRJEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-苯基咪唑 在 copper(l) iodide 、 正丁基锂 、 [2'-(amino-κN)[1,1'-biphenyl]-2-yl-κC]chloro[[5-(diphenylphosphino)-9,9-dimethyl-9H-xanthen-4-yl]diphenylphosphine-κP]palladium(II) 、 sodium hydride 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 5.0h， 生成 2-(1-methyl-4-phenyl-1H-imidazol-2-ylethynyl)-quinazoline
  参考文献：
  名称：

  [EN] IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE
  [FR] COMPOSÉS ORGANIQUES IMIDAZOLES ET LEUR UTILISATION CONTRE LA MALADIE INTESTINALE INFLAMMATOIRE

  摘要：

  The present invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, and/or N-oxide thereof. The invention also relates to the processes for the preparation of those compounds, pharmaceutical compositions comprising those compounds, and the uses of those compounds in treating diseases or conditions associated with inflammatory bowel disease (IBD), in particular ulcerative colitis (UC) and Crohn's disease (CD).

  公开号：

  WO2023007185A1

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'INHIBITEURS DE L'ENZYME PDE10A
  申请人：LUNDBECK & CO AS H

  公开号：WO2013050527A1

  公开（公告）日：2013-04-11

  This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

  这项发明涉及一类PDE10A酶抑制剂化合物。该发明提供了一种包含该发明化合物的治疗有效量和药用可接受载体的药物组合物。本发明还提供了制备式I化合物的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有药物成瘾的受试者的方法，包括向受试者施用式I化合物的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I化合物的治疗有效量。